PE20211599A1 - Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana - Google Patents

Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana

Info

Publication number
PE20211599A1
PE20211599A1 PE2021000286A PE2021000286A PE20211599A1 PE 20211599 A1 PE20211599 A1 PE 20211599A1 PE 2021000286 A PE2021000286 A PE 2021000286A PE 2021000286 A PE2021000286 A PE 2021000286A PE 20211599 A1 PE20211599 A1 PE 20211599A1
Authority
PE
Peru
Prior art keywords
prevention
night
migrana
meditan
prolonged administration
Prior art date
Application number
PE2021000286A
Other languages
English (en)
Inventor
Robert Russell Conley
Gudarz Davar
Kirk Willis Johnson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20211599A1 publication Critical patent/PE20211599A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invencion se refiere al uso prolongado de lasmiditan por la noche para la prevencion de la migrana, particularmente la migrana resistente al tratamiento que se define en el presente documento como migrana refractaria a dos o mas esquemas de prevencion o tratamiento previos de monoterapia y/o terapia doble.
PE2021000286A 2018-09-04 2019-09-03 Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana PE20211599A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862726585P 2018-09-04 2018-09-04
PCT/US2019/049340 WO2020051137A1 (en) 2018-09-04 2019-09-03 Chronic nightly dosing of lasmiditan for migraine prevention

Publications (1)

Publication Number Publication Date
PE20211599A1 true PE20211599A1 (es) 2021-08-18

Family

ID=68051892

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000286A PE20211599A1 (es) 2018-09-04 2019-09-03 Administracion prolongada de lasmiditan por la noche para la prevencion de la migrana

Country Status (35)

Country Link
US (1) US20210338655A1 (es)
EP (2) EP3846810B1 (es)
JP (2) JP7321256B2 (es)
KR (1) KR102649644B1 (es)
CN (1) CN112638383A (es)
AU (2) AU2019336667B2 (es)
BR (1) BR112021002945A2 (es)
CA (1) CA3111205A1 (es)
CL (1) CL2021000529A1 (es)
CO (1) CO2021002766A2 (es)
CR (1) CR20210126A (es)
DK (1) DK3846810T3 (es)
DO (1) DOP2021000039A (es)
EA (1) EA202190440A1 (es)
EC (1) ECSP21015491A (es)
ES (1) ES2967665T3 (es)
FI (1) FI3846810T3 (es)
HR (1) HRP20231587T1 (es)
HU (1) HUE064519T2 (es)
IL (1) IL281208A (es)
JO (1) JOP20210033A1 (es)
LT (1) LT3846810T (es)
MA (1) MA53551B1 (es)
MD (1) MD3846810T2 (es)
MX (1) MX2021002474A (es)
NZ (1) NZ774400A (es)
PE (1) PE20211599A1 (es)
PH (1) PH12021550448A1 (es)
PL (1) PL3846810T3 (es)
PT (1) PT3846810T (es)
RS (1) RS64857B1 (es)
SG (1) SG11202101530PA (es)
SI (1) SI3846810T1 (es)
TW (1) TWI826514B (es)
WO (1) WO2020051137A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015119848A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
CA3190176A1 (en) * 2020-07-29 2022-02-03 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
WO2010115125A2 (en) * 2009-04-02 2010-10-07 Colucid Pharmaceuticals, Inc. Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2011123654A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists

Also Published As

Publication number Publication date
SI3846810T1 (sl) 2023-12-29
CL2021000529A1 (es) 2021-08-13
MA53551A (fr) 2022-01-12
TWI826514B (zh) 2023-12-21
AU2019336667B2 (en) 2022-09-29
JP7321256B2 (ja) 2023-08-04
DOP2021000039A (es) 2021-03-31
HUE064519T2 (hu) 2024-03-28
PT3846810T (pt) 2023-12-14
KR102649644B1 (ko) 2024-03-21
TW202033197A (zh) 2020-09-16
JOP20210033A1 (ar) 2021-02-25
WO2020051137A1 (en) 2020-03-12
CR20210126A (es) 2021-04-22
SG11202101530PA (en) 2021-03-30
ES2967665T3 (es) 2024-05-03
AU2019336667A1 (en) 2021-03-11
CA3111205A1 (en) 2020-03-12
MA53551B1 (fr) 2023-11-30
LT3846810T (lt) 2024-01-10
US20210338655A1 (en) 2021-11-04
EP3846810B1 (en) 2023-10-18
ECSP21015491A (es) 2021-04-29
MD3846810T2 (ro) 2024-04-30
KR20210039419A (ko) 2021-04-09
EA202190440A1 (ru) 2021-06-24
AU2022291568A1 (en) 2023-02-02
BR112021002945A2 (pt) 2021-05-11
HRP20231587T1 (hr) 2024-03-15
PH12021550448A1 (en) 2021-09-27
FI3846810T3 (fi) 2023-12-15
EP3846810A1 (en) 2021-07-14
CO2021002766A2 (es) 2021-03-19
IL281208A (en) 2021-04-29
EP4279132A2 (en) 2023-11-22
CN112638383A (zh) 2021-04-09
DK3846810T3 (da) 2023-12-04
EP4279132A3 (en) 2024-03-06
NZ774400A (en) 2024-03-22
JP2021535913A (ja) 2021-12-23
JP2023156344A (ja) 2023-10-24
RS64857B1 (sr) 2023-12-29
PL3846810T3 (pl) 2024-03-18
MX2021002474A (es) 2021-08-24

Similar Documents

Publication Publication Date Title
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
DOP2021000039A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
CL2018003588A1 (es) Uso de inhibidores de miostatina y terapias de combinación.
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
CL2020000301A1 (es) Nuevos derivados de quinolina.
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900099A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CR20190447A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral de dengue
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
CL2019003078A1 (es) Nuevos derivados de pirazol bicíclicos.
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
EA201691570A1 (ru) Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer
CO2019009020A2 (es) Derivados de pirazol como inhibidores de bromodominio.